MannKind Corp. founder and recently named chairman emeritus Alfred Mann died on Feb. 25, leaving behind a biomedical legacy that extends far beyond his namesake company.
MannKind Corp. founder and recently named chairman emeritus Alfred Mann died on Feb. 25, leaving behind a biomedical legacy that extends far beyond his namesake company.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
With the FDA asking for another Phase III trial, the short bowel syndrome drug apraglutide could be years away from market, while the Linzess patent expiry and near-term debt loom.
The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.
The end of semaglutide and tirzepatide shortages means large-scale compounding is declining, ICER noted. But compounded versions – and the demand for them – are likely here to stay.
Adstiladrin sales hit €70m in first full year on the market
The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.
Bristol Myers Squibb notched two approvals in one week for its immuno-oncology combination, pitting the regimen head-to-head with Keytruda in a subset of CRC and with two combos in HCC.
The company presented positive Phase III data from a subset analysis of ICONIC-LEAD comprising patients with moderate-to-severe plaque psoriasis.
